This is the first multicountry analysis of six large contemporary population-based studies, and shows that all-cause mortality in people with type 1 diabetes has declined in recent years in most studied populations. However, excess mortality relative to the population without diabetes remains high in people with type 1 diabetes (Diabetologia)
Diabetes News
Tag: Type 1 Diabetes
Exploratory study reveals far reaching systemic and cellular effects of verapamil treatment in subjects with type 1 diabetes
The current studies provide crucial mechanistic and clinical insight into the beneficial effects of verapamil in T1D (Nature)
The Gut Microbiome of Adults With Type 1 Diabetes and Its Association With the Host Glycemic Control
We identified a distinct gut microbial signature in adults with longstanding T1D and associations between microbial taxa, metabolic pathways, and glycemic control indices (Diabetes Care)
Real-world Evidence of Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Therapy in Adults With Type 1 Diabetes: A European Two-Center Experience
Our real-world data on SGLT2i showed promising results in reductions in HbA1c, weight, and insulin requirements in type 1 diabetes. Benefits were more pronounced in individuals with higher baseline HbA1c and BMI. DKA remained a major concern, despite educational measures (Diabetes Care)
Joint 30-year HbA1c and lipid trajectories and mortality in type 1 diabetes
These results suggest there is a subgroup with type 1 diabetes who, despite poor glycemic control, has a relatively good prognosis, perhaps related to good Non-HDLc (Diabetes Research and Clinical Practice)
Effectiveness of continuous glucose monitoring in maintaining glycaemic control among people with type 1 diabetes mellitus
CGM is superior to SMBG in improving glycaemic control among individuals with type 1 diabetes in the community, especially in those with uncontrolled glycaemia (Diabetologia)
Intra-lymphatic administration of GAD-alum in type 1 diabetes: long-term follow-up and effect of a late booster dose (the DIAGNODE Extension trial)
The effect of intra-lymphatic injections of GAD-alum had decreased after 30 months. Good responders showed a specific immune response. Administration of a fourth booster dose after 31.5 months was safe, and there was no decline in C-peptide observed during the 12-month follow-up (Acta Diabetologica)
A systematic review of the prevalence, risk factors and screening tools for autonomic and diabetic peripheral neuropathy in children, adolescents and young adults with type 1 diabetes
Prevalence of neuropathy in youth with type 1 diabetes varies depending on different screening methods and characteristics of the study populations. However, the assessed studies confirmed a relatively high prevalence of subclinical neuropathy, reiterating the importance of early identification of risk factors to prevent this complication (Acta Diabetologica)
Glomerular filtration rate abnormalities in children with type 1 diabetes
A notable proportion of children with T1D demonstrate eGFR abnormalities early in their T1D course. This finding along with evidence of eGFR declining over time is concerning for long-term risk of CKD and warrants systematic serum creatinine monitoring at diagnosis and regular intervals thereafter in children with T1D (Canadian Journal of Diabetes)
Continuous Glucose Monitoring in Adults With Type 1 Diabetes With 35 Years Duration From the DCCT/EDIC Study
The small subset of participants using routine CGM and insulin pumps had fewer hypoglycemic and hyperglycemic excursions and lower HbA1c levels. Thus, strategies to lower meal-stimulated hyperglycemia during the day and prevent hypoglycemia at night are relevant clinical goals in older patients with type 1 diabetes (Diabetes Care)
ZT-01 – A Novel Somatostatin Receptor Antagonist for Restoring the Glucagon Response to Hypoglycemia in Type 1 Diabetes
We conclude that ZT-01 may be effective in restoring glucagon responses and preventing the onset of hypoglycemia in patients with T1D (Diabetes, Obesity and Metabolism)
Changes of insulin resistance status and development of complications in type 1 diabetes mellitus: Analysis of DCCT/EDIC study
This study highlights the importance of IR changes represented by eGDR in the development of diabetic complications. Patients with T1D and IR may require intensive therapy (Diabetes Research and Clinical Practice)
Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes
A hybrid closed-loop system significantly improved glycemic control in very young children with type 1 diabetes, without increasing the time spent in hypoglycemia (NEJM)
Characterising the age-dependent effects of risk factors on type 1 diabetes progression
Analysing the age-varying effect of disease predictors improves understanding and prediction of type 1 diabetes disease progression, and should be leveraged to refine prediction models and guide mechanistic studies (Diabetologia)
Randomized controlled study to evaluate the impact of flexible patient-controlled visits in people with type 1 diabetes: The DiabetesFlex Trial
Compared with standard care, flexible patient-controlled visits combined with patient-reported outcomes in participants with metabolic controlled type 1 diabetes and good psychological well-being further improved diabetes-related well-being and decreased face-to-face visits while maintaining safe diabetes management (Diabetic Medicine)
A Practical Approach to Continuous Glucose Monitoring (rtCGM) and FreeStyle Libre systems (isCGM) in Children and Young people with Type 1 Diabetes
This article, aims to provide a practical approach and help identify which patients may be most likely to benefit and how the technology may be implemented in order to maximise the clinical benefits (Diabetes Research and Clinical Practice)
Comparisons of biochemical parameters and diabetic ketoacidosis severity in adult patients with type 1 and type 2 diabetes
There are no differences in DKA-related biochemical parameters between type 1 and type 2 diabetes patients. The present findings suggest that DKA should be assessed and treated similarly, regardless of its occurrence in type 1 or type 2 diabetes patients (BMC Endocrine Disorders)
How low is really low? Comparison of two C-peptide assays to establish residual C-peptide production in type 1 diabetes
The IRMA provided the lowest threshold for quantification of serum C-peptide. LoQ of commercially available assays should be established in-house before applying them in research studies and clinical trials in which low C-peptide levels have clinical or scientific relevance (Diabetic Medicine)
Standards of Medical Care in Diabetes—2022
Professional Practice Committee: Standards of Medical Care in Diabetes—2022 (Diabetes Care)
The Role of Glucagon in Glycemic Variability in Type 1 Diabetes: A Narrative Review
There is growing evidences to illustrate the contribution of glucagon secretion to the glycemic variability in patients with T1DM, which may promote the development of new treatment strategies aiming to mitigate glycemic variability associated with aberrant glucagon secretion (Metabolic Syndrome and Obesity)
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 22
- Next Page »
Glycosmedia is also available as an App: